07:00 , Jun 21, 2010 |  BC Week In Review  |  Company News

Arginetix, Immune Control deal

Arginetix and Immune Control merged to form Corridor Pharmaceuticals Inc. The newco will develop therapies for vascular diseases, initially focusing on pulmonary arterial hypertension (PAH). Corridor, which will be based in Baltimore, has designated Immune...
07:00 , Jun 21, 2010 |  BioCentury  |  Finance

Friendly persuasion

Arginetix Inc. and Immune Control Inc. agreed to merge last week in a union officiated by Quaker BioVentures, which saw an opportunity to combine a pair of early-stage portfolio companies in the same space. Gary...
00:22 , Jun 18, 2010 |  BC Extra  |  Company News

Arginetix, Immune Control merge, raise $15 million

Arginetix Inc. (Baltimore, Md.) and Immune Control Inc. (West Conshohocken, Pa.) merged to form Corridor Pharmaceuticals Inc. and raised $15 million in a series A round. The combined company is developing therapies for vascular diseases,...
08:00 , Dec 7, 2009 |  BioCentury  |  Emerging Company Profile

Another NO to PAH: Sidebar: Corporate Profile

Arginetix Inc. Baltimore, Md. Technology: Small molecule arginase inhibitors Disease focus: Cardiovascular, inflammation Clinical status: Preclinical Founded: 2007 by Gary Lessing, Dan Berkowitz and David Christianson University collaborators: University of Pennsylvania and Johns Hopkins University...
08:00 , Dec 7, 2009 |  BioCentury  |  Emerging Company Profile

Arginetix: Another NO to PAH

Marketed therapeutics that target the endothelin, prostacyclin or nitric oxide pathways have improved the outcomes for patients with pulmonary arterial hypertension, yet mortality remains high. Arginetix Inc. believes its arginase inhibitors could complement marketed therapeutics...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Financial News

Arginetix completes venture financing

Arginetix Inc. , Baltimore, Md.   Business: Cardiovascular, Genitourinary   Date completed: 10/2/09   Type: Venture financing   Raised: $10.8 million   Investors: Quaker BioVentures; MedImmune Ventures; Maryland Health Care Product Development Corp.; Osage University...
00:29 , Oct 3, 2009 |  BC Extra  |  Financial News

Arginetix raises $10.8 million

Arginetix Inc. (Baltimore, Md.) raised $10.8 million in a series A round co-led by Quaker BioVentures and MedImmune Ventures. Additional investors included Maryland Health Care Product Development Corp.; Osage University Partners; Red Abbey; and company...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Company News

Arginetix, University of Pennsylvania deal

The university granted newco Arginetix an exclusive, worldwide license to IP covering the composition of matter and therapeutic uses of small molecule inhibitors of arginase. The university received an undisclosed equity stake in Arginetix, which...